Study to Evaluate the Safety and Efficacy of Two Different Dosing Schedules of Pembrolizumab (MK-3475) Compared to Ipilimumab in Participants With Advanced Melanoma (MK-3475-006/KEYNOTE-006)

NCT01866319 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

834

Enrollment

INDUSTRY

Sponsor class

Conditions

Melanoma

Interventions

BIOLOGICAL: Pembrolizumab
BIOLOGICAL: Ipilimumab

Sponsor

Merck Sharp & Dohme LLC